Table 2 Clinical and laboratory characteristics of patients with diabetic and non-diabetic IHD
From: Incidence of heart failure among diabetic patients with ischemic heart disease: a cohort study
Variables | All patients (n = 306) | DM | P-value* | |
|---|---|---|---|---|
Yes (n = 96, 31.4%) | No (n = 210, 68.6%) | |||
Heart Failure | ||||
Yes | 196 (64.1) | 70 (72.9) | 126 (60.0) | 0.029 |
No | 110 (35.9) | 26 (27.1) | 84 (40.0) | 1.00 |
Corombidities | ||||
Yes | 168 (54.9) | 61 (63.5) | 107 (51.0) | 0.04 |
No | 138 (45.1) | 35 (36.5) | 103 (49.0) | 1.00 |
Type of Comorbidities | ||||
HTN | 144 (47.1) | 53 (55.2) | 91 (43.3) | 0.07 |
Dyslipidemia at baseline | 48 (15.7) | 25 (26.0) | 23 (11.0) | 0.001 |
Cerebrovascular accident | 15 (4.9) | 1 (1.0) | 14 (6.7) | 0.06 |
Peripheral arterial disease | 3 (1.0) | 1 (1.0) | 2 (1.0) | 1.0 |
Clinical status | ||||
NYHA class 3–4 HF (%) | 85 (27.8) | 40 (41.7) | 45 (21.4) | < 0.0001 |
SBP (mmHg)-baseline | 129.38 +/−19.20 | 132.20 +/−22.71 | 128.15 +/−17.34 | 0 .14 |
DBP (mmHg)-baseline | 80.25 +/−9.68 | 80.77 +/− 9.76 | 80.02 +/− 9.65 | 0.55 |
Laboratory Data mean or n (%) | ||||
LVEF | 46.3 +/−13.4 | 44.7 +/−12.3 | 47.1 +/− 13.8 | 0.2 |
LVDd (mm) | 51.2 +/−10.3 | 51.8 +/−9.3 | 50.9 +/−10.8 | 0.57 |
LAD (mm) | 36.7 +/−6.8 | 37.0 +/−6.6 | 36.6 +/− 6.9 | 0.98 |
Hemoglobin (g/dl) | 14.4 +/−2.0 | 14.6 +/−1.7 | 14.3 +/− 2.1 | 0.30 |
WBC count (mm3) | 7943.9 +/− 2848.3 | 8318.7 +/− 2561 | 7772.1 +/− 2962.6 | 0.18 |
Nephropathy (%) | 103 (33.7) | 34 (35.4) | 69 (32.9) | 0.7 |
Medications (%) | ||||
Aspirin | 281 (91.8) | 92 (95.8) | 189 (90.0) | 0.1 |
Statins | 261 (85.3) | 87 (90.6) | 174 (82.9) | 0.1 |
B-blockers | 254 (83.0) | 83 (86.5) | 171 (81.4) | 0.4 |
RAS inhibitors | 252 (82.4) | 81 (84.4) | 171 (81.4) | 0.6 |
Loop diuretics | 121 (39.5) | 38 (39.6) | 83 (39.5) | 1.0 |
Aldosterone antagonists | 78 (25.5) | 21 (21.9) | 57 (27.1) | 0.4 |
Clopidogrel | 32 (10.5) | 11 (11.5) | 21 (10.0) | 0.9 |
Digoxin | 27 (8.8) | 4 (4.2) | 23 (11.0) | 0.09 |
Hydrochlorthiazide | 42 (13.7) | 16 (16.7) | 26 (12.4) | 0.4 |
Calcium channel blocker | 34 (11.1) | 14 (14.6) | 20 (9.5) | 0.3 |
Use of antidiabetic medication | 96 (31.4) | 96 (100) | – | |
Insulin | 24 (7.8) | 24 (100) | – | |
Metformin | 85 (14.1) | 85 (100) | – | |
Sulfonilureas | 12 (3.9) | 12 (100) | – | |